COVID-19

[Lancet Infectious Diseases] Using national COVID-19 notification, hospitalization, and vaccination datasets from Brazil, researchers did a test-negative, case-control study to assess the effectiveness of four vaccines for individuals with laboratory-confirmed previous SARS-CoV-2 infection.

[Nature Reviews Neurology] The authors discuss what is known about the effects of various immunotherapies on immunological responses to vaccines and what these effects mean for the safe and effective use of vaccines in patients with a neuroimmunological disease.

[Scientific Reports] Scientists reported that imatinib, an Abl tyrosine kinase inhibitor, robustly decreased SARS-CoV-2 infection and uncovered a mechanism of action.

[Heliyon] Investigators identified and ranked clinical and immunological features associated with progression to severe COVID-19 in order to investigate an immunological signature of severe disease.

[Nature Cancer] The authors presented the PROSECO prospective observational study on 457 patients with lymphoma that received two or three COVID-19 vaccine doses and showed undetectable humoral responses following two vaccine doses in 52% of patients undergoing active anticancer treatment.

[Signal Transduction and Targeted Therapy] Scientists demonstrated mAb 35B5 efficiently neutralizes both wild-type (WT) SARS-CoV-2 and variants of concern, including B.1.617.2 variant, in vitro and in vivo.